ATE535257T1 - Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin - Google Patents

Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin

Info

Publication number: ATE535257T1
Authority: AT; Austria
Prior art keywords: formulation; methylsulfonylmethane; ciprofloxacin; treatment; ophthalmological formulation
Prior art date: 2005-07-15

Application number

AT06787575T

Other languages

English (en)

Inventor

Rajiv Bhushan

Jerry Gin

Original Assignee

Chakshu Res Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-15

Filing date

2006-07-14

Publication date

2011-12-15

2005-07-15 Priority claimed from US11/183,479 external-priority patent/US20060177430A1/en

2006-07-14 Application filed by Chakshu Res Inc filed Critical Chakshu Res Inc

2006-07-14 Priority claimed from PCT/US2006/027685 external-priority patent/WO2007011874A2/en

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535257T1 publication Critical patent/ATE535257T1/de

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title 2
229960003405 ciprofloxacin Drugs 0.000 title 1
229940016409 methylsulfonylmethane Drugs 0.000 title 1
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 title 1
238000000034 method Methods 0.000 abstract 3
239000013543 active substance Substances 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000008021 deposition Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT06787575T 2005-07-15 2006-07-14 Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin ATE535257T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11/182,998 US20060172972A1 (en)	2002-12-20	2005-07-15	Formulation and method for administration of ophthalmologically active agents
US11/183,479 US20060177430A1 (en)	2002-12-20	2005-07-15	Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
PCT/US2006/027685 WO2007011874A2 (en)	2005-07-15	2006-07-14	Formulation and method for administration of ophthalmologically active agents

Publications (1)

Publication Number	Publication Date
ATE535257T1 true ATE535257T1 (de)	2011-12-15

Family

ID=39996624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06787575T ATE535257T1 (de)	2005-07-15	2006-07-14	Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin

Country Status (6)

Country	Link
US (1)	US20060172972A1 (de)
JP (1)	JP2009501726A (de)
CN (1)	CN101262886A (de)
AT (1)	ATE535257T1 (de)
EA (1)	EA200800337A1 (de)
IL (1)	IL188789A0 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101262887A (zh) *	2005-07-15	2008-09-10	视可舒研究公司	糖尿病的眼科并发症的预防和治疗
US8492334B2 (en) *	2007-06-21	2013-07-23	Yale University	Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US9616127B2 (en) *	2008-03-11	2017-04-11	Livionex Inc.	Method and topical formulation for treating localized edema
US10463677B2 (en) *	2008-11-07	2019-11-05	Cydex Pharmaceuticals, Inc.	Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) *	2009-05-22	2010-11-25	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
ES2964555T3 (es)	2009-08-24	2024-04-08	Stealth Biotherapeutics Inc	Péptido para uso en la prevención o tratamiento de la degeneración macular
KR20120095371A (ko) *	2009-10-01	2012-08-28	에보닉 데구사 코포레이션	노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
KR101845107B1 (ko) *	2010-08-17	2018-04-03	오에이치알 파마서티컬, 인코포레이티드	스쿠알라민 안약 제제
US9622911B2 (en)	2010-09-30	2017-04-18	Cxl Ophthalmics, Llc	Ophthalmic treatment device, system, and method of use
WO2012136969A2 (en) *	2011-04-05	2012-10-11	Anant Sharma	Ophthalmic treatments
WO2013149075A1 (en)	2012-03-29	2013-10-03	Cxl Ophthalmics, Llc	Compositions and methods for treating or preventing diseases associated with oxidative stress
US9555111B2 (en)	2012-03-29	2017-01-31	Cxl Ophthalmics, Llc	Ocular cross-linking system and method for sealing corneal wounds
EP4420725A3 (de)	2012-03-29	2025-04-16	Epion Therapeutics, Inc.	Augenbehandlungslösungen, abgabevorrichtungen und abgabeverstärkungsverfahren
US10507245B2 (en)	2012-07-19	2019-12-17	Luis Felipe Vejarano Restrepo	Ophthalmic formulation and method for ameliorating presbyopia
RU2694758C2 (ru) *	2012-12-20	2019-07-16	Раджив Бхушан	Антимикробные композиции
US20150164882A1 (en)	2013-07-22	2015-06-18	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en)	2013-07-22	2016-09-29	Imprimis Pharmaceuticals, Inc.	Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US9089562B2 (en) *	2013-08-28	2015-07-28	Presbyopia Therapies Llc	Compositions and methods for the treatment of presbyopia
US11179327B2 (en) *	2013-08-28	2021-11-23	Lenz Therapeutics, Inc.	Compositions and methods for the treatment of presbyopia
US20170246176A1 (en) *	2014-10-31	2017-08-31	Keio University	Phacosclerosis inhibitor
TW201720446A (zh) *	2015-11-13	2017-06-16	Ｏｈｒ製藥公司	非典型脈絡膜新生血管（ｃｎｖ）之大小做為以角鯊胺治療之預測子
WO2019153019A1 (en) *	2018-02-05	2019-08-08	LIVIONEX, Inc.	Formulations comprising chelators, permeation enhancers and hydroxyethyl cellulose for treating ophthalmic disorders
CN109091675B (zh) *	2018-08-31	2021-09-17	杭州赫尔斯科技有限公司	一种复方低浓度阿托品类药物滴眼液及其制备方法
US20210251970A1 (en)	2018-10-10	2021-08-19	Presbyopia Therapies Inc	Compositions and methods for storage stable ophthalmic drugs
EP3894405A4 (de) *	2018-12-05	2022-09-28	Presbyopia Therapies, Inc.	Prodrugs von chinuclidinring-haltigen muscarinagonisten und zusammensetzungen und verfahren dafür
CN112823784B (zh) *	2019-11-20	2022-09-16	湖北远大天天明制药有限公司	吡诺克辛钠滴眼液以及用于眼部给药的溶液
WO2023091439A1 (en)	2021-11-17	2023-05-25	Lenz Therapeutics, Inc.	Aceclidine derivatives, compositions thereof and methods of use thereof
US20230310380A1 (en) *	2022-04-05	2023-10-05	Alan Neil Glazier	Methods, devices, and systems for treating lens protein aggregation diseases
US12414942B1 (en)	2024-03-15	2025-09-16	Lenz Therapeutics Operations, Inc.	Compositions, methods, and systems for treating presbyopia

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en) *	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4087538A (en) *	1976-09-09	1978-05-02	Merck & Co., Inc.	Ophthalmic suspensions
US4294853A (en) *	1979-06-13	1981-10-13	Abbott Laboratories	Biocidal additive for cutting fluids
US4863748A (en) *	1979-08-30	1989-09-05	Herschler R J	Dietary products and uses comprising methylsulfonylmethane
US4390542A (en) *	1980-12-02	1983-06-28	Schachar Ronald A	Method for inhibiting contraction of opthalmic wounds or incisions
US4510145A (en) *	1980-12-02	1985-04-09	Schachar Ronald A	Method for inhibiting contraction of ophthalmic wounds or incisions
FR2588189B1 (fr) *	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
US5032392A (en) *	1986-09-04	1991-07-16	Vision Pharmaceuticals	Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4853224A (en) *	1987-12-22	1989-08-01	Visionex	Biodegradable ocular implants
US4923693A (en) *	1988-01-21	1990-05-08	Sundrops Enterprises, Inc.	Ultraviolet radiation screening method for eyes
US5360611A (en) *	1988-10-03	1994-11-01	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5278142A (en) *	1989-03-20	1994-01-11	Orbon Corporation	Systemic delivery of polypeptides through the eye
US5182258A (en) *	1989-03-20	1993-01-26	Orbon Corporation	Systemic delivery of polypeptides through the eye
US5221696A (en) *	1989-03-29	1993-06-22	Alcon Laboratories, Inc.	Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5660851A (en) *	1989-12-26	1997-08-26	Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem	Ocular inserts
US5300295A (en) *	1990-05-01	1994-04-05	Mediventures, Inc.	Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5525601A (en) *	1990-09-07	1996-06-11	Universidad De Alicante	Composition for treating ocular pain
US5561110A (en) *	1991-09-09	1996-10-01	Peptide Technology Limited	Method for the treatment of the complications and pathology of diabetes
ZA927277B (en) *	1991-10-02	1993-05-19	Boston Ocular Res	Dry eye treatment process and solution.
US5270051A (en) *	1991-10-15	1993-12-14	Harris Donald H	Enzyme-orthokeratology
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US6015834A (en) *	1992-10-20	2000-01-18	Toronto Neuroprotection Group	In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
US5443505A (en) *	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
JPH09505057A (ja) *	1993-11-19	1997-05-20	ザ・ユニバーシティ・オブ・シドニー	白内障を予防または制御するための方法
US5443824A (en) *	1994-03-14	1995-08-22	Piacquadio; Daniel J.	Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
WO1995034302A2 (en) *	1994-06-16	1995-12-21	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
FI119756B (fi) *	1995-01-18	2009-03-13	Alteon Inc	Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
DE69629176T2 (de) *	1995-01-18	2004-06-03	Alteon Inc.	Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
US5824685A (en) *	1995-02-01	1998-10-20	The Johns Hopkins University School Of Medicine	Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6492420B2 (en) *	1995-03-10	2002-12-10	Photocure As	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
WO1998016214A1 (en) *	1996-10-14	1998-04-23	Kissei Pharmaceutical Co., Ltd.	Secondary cataract inhibitor
US6410046B1 (en) *	1996-11-19	2002-06-25	Intrabrain International Nv	Administering pharmaceuticals to the mammalian central nervous system
MX9701946A (es) *	1997-03-14	1998-04-30	Arturo Jimenez Bayardo	Solucion oftalmica transportadora.
US5817630A (en) *	1997-03-18	1998-10-06	Austin Nutriceutical Corporation	Glutathione antioxidant eye drops
WO1998043611A1 (en) *	1997-03-31	1998-10-08	Alza Corporation	Diffusional implantable delivery system
US5811446A (en) *	1997-04-18	1998-09-22	Cytos Pharmaceuticals Llc	Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6265444B1 (en) *	1997-05-23	2001-07-24	Insite Vision Incorporated	Ophthalmic composition
US6159458A (en) *	1997-11-04	2000-12-12	Insite Vision	Sustained release ophthalmic compositions containing water soluble medicaments
US6555522B1 (en) *	1998-02-05	2003-04-29	Mount Sinai School Of Medicine Of The City Of New York	Peptides and other small molecules derived from regions of interacting proteins and uses thereof
US6197934B1 (en) *	1998-05-22	2001-03-06	Collagenesis, Inc.	Compound delivery using rapidly dissolving collagen film
BR9914813A (pt) *	1998-10-27	2001-07-03	Alcon Lab Inc	Sistema conservante para composições farmacêuticas administráveis topicamente
US6171337B1 (en) *	1999-03-31	2001-01-09	Miles A. Galin	Positive power anterior chamber ocular implant
CA2368688C (en) *	1999-04-05	2009-08-11	City Of Hope	Novel inhibitors of formation of advanced glycation endproducts (age's)
US6548059B1 (en) *	1999-07-22	2003-04-15	The Schepens Eye Research Institute, Inc.	Promotion of proliferation of adult corneal endothelial cells
EP1212093B1 (de) *	1999-08-26	2004-07-07	Ganeden Biotech, Inc.	Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
US6573299B1 (en) *	1999-09-20	2003-06-03	Advanced Medical Instruments	Method and compositions for treatment of the aging eye
US6653352B2 (en) *	1999-09-29	2003-11-25	Medical Merchandising, Inc.	Pain reliever and method of use
AU1191001A (en) *	1999-10-07	2001-05-10	Human Genome Sciences, Inc.	Plasminogen-like polynucleotides, polypeptides, and antibodies
US6331313B1 (en) *	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
US6348508B1 (en) *	2000-04-04	2002-02-19	Bausch & Lomb Incorporated	Method for treating dry eye
RU2165749C1 (ru) *	2000-07-06	2001-04-27	Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза"	Способ восстановления эндотелия роговицы
EP1328214A4 (de) *	2000-09-20	2009-07-29	Shahinian Lee Jr	Selbstkonservierende nasale, inhalierbare und topische ophthalmische präparate und medikamente
US6328987B1 (en) *	2000-11-03	2001-12-11	Jan Marini Skin Research, Inc.	Cosmetic skin care compositions containing alpha interferon
US7084130B2 (en) *	2001-12-11	2006-08-01	Alcon, Inc.	Intraocular irrigating solution having improved flow characteristics
US6713081B2 (en) *	2001-03-15	2004-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Ocular therapeutic agent delivery devices and methods for making and using such devices
US6533769B2 (en) *	2001-05-03	2003-03-18	Holmen Joergen	Method for use in cataract surgery
WO2002100455A2 (en) *	2001-06-08	2002-12-19	Baylor College Of Medicine	Use of ozone for the prevention of infection caused by medical devices
US20030083286A1 (en) *	2001-08-22	2003-05-01	Ching-Leou Teng	Bioadhesive compositions and methods for enhanced intestinal drug absorption
DE60239952D1 (de) *	2001-11-14	2011-06-16	Durect Corp	Injizierbare depotzusammensetzungen und deren verwendung
US20030114460A1 (en) *	2001-12-14	2003-06-19	Allergan Sales, Inc.	Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
NZ540885A (en) *	2002-12-20	2009-02-28	Chakshu Res Inc	Ophthalmic formulation for the prevention and treatment of ocular conditions

2005
- 2005-07-15 US US11/182,998 patent/US20060172972A1/en not_active Abandoned
2006
- 2006-07-14 CN CNA2006800339508A patent/CN101262886A/zh active Pending
- 2006-07-14 AT AT06787575T patent/ATE535257T1/de active
- 2006-07-14 JP JP2008521703A patent/JP2009501726A/ja active Pending
- 2006-07-14 EA EA200800337A patent/EA200800337A1/ru unknown
2008
- 2008-01-15 IL IL188789A patent/IL188789A0/en unknown

Also Published As

Publication number	Publication date
IL188789A0 (en)	2008-12-29
CN101262886A (zh)	2008-09-10
JP2009501726A (ja)	2009-01-22
EA200800337A1 (ru)	2008-08-29
US20060172972A1 (en)	2006-08-03

Publication	Publication Date	Title
ATE535257T1 (de)	2011-12-15	Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
EP2322219A3 (de)	2013-06-05	Verwendung von IL-23- und IL-17-Antagonisten zur Behandlung von Augenentzündungsautoimmunerkrankungen
WO2019209962A8 (en)	2020-04-09	Compounds and uses thereof
NO20075660L (no)	2008-02-22	Blanding for behandling av inflammatoriske sykdommer
DE602006006308D1 (de)	2009-05-28	Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
EA201300272A1 (ru)	2013-07-30	Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
WO2019209948A8 (en)	2019-11-28	Compounds and uses thereof
MX2007005570A (es)	2007-07-09	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2008029276A8 (en)	2009-08-06	Compositions and methods for the treatment of ophthalmic disease
ATE496623T1 (de)	2011-02-15	Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
MX2020009942A (es)	2021-01-08	Compuestos y usos de los mismos.
CY1108676T1 (el)	2014-04-09	Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
NO20064521L (no)	2007-02-06	Framgangsmate og blanding for behandling av rhinitt
PT1864668E (pt)	2013-02-26	Utilização de pró-fármacos para administração ocular intravítrea
WO2007067519A3 (en)	2007-12-06	The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
ATE477805T1 (de)	2010-09-15	9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
WO2007077203A3 (en)	2007-08-30	Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
ATE495735T1 (de)	2011-02-15	Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
DE602006017997D1 (de)	2010-12-16	Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel
WO2021247916A8 (en)	2022-01-27	Azetidine and spiroazetidine compounds and uses thereof
WO2021247921A8 (en)	2022-01-27	Benzothiazole compounds and uses thereof
MX2010005009A (es)	2010-05-27	Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
BRPI0811223A2 (pt)	2014-10-29	Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica.
RU2004105876A (ru)	2005-08-10	Способ лечения и профилактики глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
CL2008002951A1 (es)	2009-10-02	Compuestos derivados de alcoxifenilalquilaminas, inhibidores de la produccion de 11-cis-retinol; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o desorden oftalmico tal como desprendimiento de la retina, neuropatia diabetica, miopia y un trastorno retinal asociado con sida.